Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Also, Amgen’s weight loss drug had little chance to gain market share because of Lilly’s and Novo’s dominance. Data shows ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

a gastroenterologist who runs a weight loss clinic in Cary, North Carolina, tells TODAY.com. GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...